Comparative Pharmacology
Head-to-head clinical analysis: CAPOTEN versus UNIRETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOTEN versus UNIRETIC.
CAPOTEN vs UNIRETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, and increased plasma renin activity.
Uniretic is a combination of an angiotensin-converting enzyme (ACE) inhibitor (moexipril) and a thiazide diuretic (hydrochlorothiazide). Moexipril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing excretion of sodium and water.
50 mg orally three times daily initially; maintenance 50-100 mg three times daily; maximum 450 mg/day.
1-2 tablets (each containing hydrochlorothiazide 25 mg and spironolactone 25 mg) orally once daily. Maximum dose: 4 tablets/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.9 hours in healthy subjects, but prolonged in heart failure (up to 3-4 hours) and renal impairment (up to 5-10 hours).
Terminal elimination half-life 13-17 hours; clinical context: supports once-daily dosing
Primarily renal (approximately 60-75% as unchanged drug and metabolites) and biliary/fecal (approximately 20%).
Renal: 50-70% unchanged; biliary/fecal: 10-15% as metabolites
Category C
Category C
ACE Inhibitor
ACE Inhibitor and Diuretic